Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 14, Issue 8, Pages 710
Publisher
MDPI AG
Online
2021-07-23
DOI
10.3390/ph14080710
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Umbralisib: First Approval
- (2021) Sohita Dhillon et al. DRUGS
- Trilaciclib: First Approval
- (2021) Sohita Dhillon DRUGS
- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Avapritinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Tepotinib: First Approval
- (2020) Anthony Markham DRUGS
- Pemigatinib: First Approval
- (2020) Sheridan M. Hoy DRUGS
- The discovery and development of binimetinib for the treatment of melanoma
- (2020) Brian Tran et al. Expert Opinion on Drug Discovery
- Tucatinib: First Approval
- (2020) Arnold Lee DRUGS
- Selumetinib: First Approval
- (2020) Anthony Markham et al. DRUGS
- Selpercatinib: First Approval
- (2020) Anthony Markham DRUGS
- Capmatinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Ripretinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions
- (2020) Carmela Matrone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases
- (2020) Marija Buljan et al. MOLECULAR CELL
- Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
- (2020) Shanada Monestime et al. DRUGS IN R&D
- An Overview of the Role of Calcium/Calmodulin-Dependent Protein Kinase in Cardiorenal Syndrome
- (2020) Carolina Victoria Cruz Junho et al. Frontiers in Physiology
- Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma
- (2020) Gehan Botrus et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Protein Kinase Inhibitor Peptide as a Tool to Specifically Inhibit Protein Kinase A
- (2020) Chong Liu et al. Frontiers in Physiology
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Lorlatinib: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
- (2019) Robert Ali et al. Drug Design Development and Therapy
- Properties of FDA-approved small molecule protein kinase inhibitors
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Gilteritinib: First Global Approval
- (2019) Sohita Dhillon DRUGS
- Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
- (2019) Monica Capozzi et al. Cancer Management and Research
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Fedratinib: First Approval
- (2019) Hannah A. Blair DRUGS
- Pharmacological research and cancer: A call to arms
- (2019) Keiran S.M. Smalley PHARMACOLOGICAL RESEARCH
- Upadacitinib: First Approval
- (2019) Sean Duggan et al. DRUGS
- Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma
- (2019) Fangmin Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Landscape of Atypical and Eukaryotic Protein Kinases
- (2019) Georgi K. Kanev et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Preclinical and clinical development of palbociclib and future perspectives
- (2018) E. Martínez de Dueñas et al. Clinical & Translational Oncology
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- Evolution, dynamics and dysregulation of kinase signalling
- (2018) David Ochoa et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Fostamatinib: First Global Approval
- (2018) Anthony Markham DRUGS
- Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
- (2018) Linyi Liu et al. Future Medicinal Chemistry
- Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
- (2018) Cheng-Wen Lin et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Unexplored therapeutic opportunities in the human genome
- (2018) Tudor I. Oprea et al. NATURE REVIEWS DRUG DISCOVERY
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation
- (2018) Brice Martin Couillaud et al. ChemMedChem
- Dacomitinib: First Global Approval
- (2018) Matt Shirley DRUGS
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer
- (2018) Arnaud Jeanson et al. Expert Review of Anticancer Therapy
- Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer
- (2017) Giuseppe Curigliano et al. Expert Opinion on Drug Metabolism & Toxicology
- The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
- (2017) Sarah Knispel et al. Expert Opinion On Drug Safety
- Nintedanib in ovarian cancer
- (2017) Saira Khalique et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
- (2017) Tommaso De Pas et al. Future Oncology
- Insane in the membrane: a structural perspective of MLKL function in necroptosis
- (2017) Emma J Petrie et al. IMMUNOLOGY AND CELL BIOLOGY
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
- (2016) Srividya Srinivasamaharaj et al. Expert Review of Anticancer Therapy
- Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
- (2016) Wolfgang Brückl et al. Expert Review of Anticancer Therapy
- Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
- (2016) Giuseppe Procopio et al. Drug Design Development and Therapy
- Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
- (2015) Yousef Zakharia et al. Expert Opinion on Drug Discovery
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
- (2015) Benjamin Carlisle et al. JNCI-Journal of the National Cancer Institute
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
- (2015) Benjamin Carlisle et al. JNCI-Journal of the National Cancer Institute
- Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis
- (2014) Kirandeep Kaur et al. CLINICAL THERAPEUTICS
- The preclinical development of regorafenib for the treatment of colorectal cancer
- (2014) Koh Miura et al. Expert Opinion on Drug Discovery
- Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis
- (2014) Birgit Schittek et al. Molecular Cancer
- AGC protein kinases: From structural mechanism of regulation to allosteric drug development for the treatment of human diseases
- (2013) José M. Arencibia et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
- (2013) Robert Roskoski Expert Opinion on Drug Discovery
- The discovery and development of vandetanib for the treatment of thyroid cancer
- (2013) Michael W Sim et al. Expert Opinion on Drug Discovery
- Cancer Drugs in the United States: Justum Pretium—The Just Price
- (2013) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma
- (2012) A. Guarini et al. CURRENT MEDICINAL CHEMISTRY
- Temsirolimus: a safety and efficacy review
- (2012) Ronald M. Bukowski Expert Opinion On Drug Safety
- Lapatinib and renal cell carcinoma
- (2012) Marine Gross-Goupil et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nilotinib as first-line therapy for chronic myeloid leukemia
- (2012) A Vaid INDIAN JOURNAL OF CANCER
- The secret life of kinases: functions beyond catalysis
- (2011) Jens Rauch et al. Cell Communication and Signaling
- A potential role of ruxolitinib in leukemia
- (2011) Kiran Naqvi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Pazopanib: Clinical development of a potent anti-angiogenic drug
- (2010) Fabio A.B. Schutz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Protein kinase signaling networks in cancer
- (2010) John Brognard et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- (2010) Hisao Masai Drug Design Development and Therapy
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now